Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Real-time Estimate Cboe BZX Other stock markets 01:27:57 2024-04-30 pm EDT			5-day change	1st Jan Change
4.835 ^USD	-0.31%		-4.92%	-4.36%

Apr. 23	Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	CI
Mar. 12	Mizuho Adjusts Price Target on WAVE Life Sciences to $19 From $10, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)	08:30am	GL
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	Apr. 23	GL
Wave Life Sciences to Present at Upcoming Investor Conferences	Mar. 27	GL
Wave Life Sciences: Q4 Earnings Snapshot	Mar. 06	AQ
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 06	GL
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024	Feb. 28	GL
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy	Feb. 27	GL
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones	Jan. 08	GL
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	Dec. 18	AQ
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	Dec. 15	GL
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares	Dec. 07	GL
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants	Dec. 06	GL
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency	Dec. 06	GL
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference	Nov. 22	GL
Wave Life Sciences: Q3 Earnings Snapshot	Nov. 09	AQ
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 09	GL
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023	Nov. 03	GL
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day	23-09-28	GL
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference	23-09-25	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Press Releases

Filters